Anderson / Lydyard / McAllister-Williams Fundamentals of Clinical Psychopharmacology, Fourth Edition

4. Auflage 2015
ISBN: 978-1-4987-1896-7
Verlag: CRC Press
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 280 Seiten

Fundamentals of Clinical Psychopharmacology provides up-to-date, evidence-based and unbiased information about psychopharmacology. It spans the range of the discipline, from mode of action and side effects of drugs to meta-analyses of clinical trials. It is anchored to practice guidelines produced by the UK National Institute for Health and Care Excellence (NICE) and the British Association for Psychopharmacology (BAP). Care has been taken to provide an international perspective that makes it equally useful to practitioners in the US and other countries.

The book grew out of BAP courses that set the standard for professional psychopharmacological education in the UK. This latest edition is fully updated and provides, in a concise and easy-to-read format, key facts about currently used psychotropic drugs, set in the context of the neuroscience of the disorders they treat. It also includes a new chapter on the principles of psychiatric prescribing.

Key references, including the clinical studies discussed, are provided at the end of the chapter along with suggestions for further reading. Intended to be a frequently updated, affordable, concise and practical resource, it meets the needs of trainees and practitioners seeking to keep abreast of the state of the art in psychopharmacology.

Autoren/Hrsg.

Lydyard, Peter

Whelan, Peter

Fanger, Michael

Anderson, Ian M.

McAllister-Williams, R. Hamish

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Psychiatrie, Sozialpsychiatrie, Suchttherapie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie

Inhaltsverzeichnis

Neuropharmacology and Drug Action
Sarah E. Gartside and Charles A. Marsden

Pharmacokinetics and Pharmacodynamics
Ian M. Anderson

Antipsychotics
Frances Cheng, Peter B. Jones and Peter S. Talbot

Antidepressants and ECT
Chris Smart, Ian M. Anderson and R. Hamish McAllister-Williams

‘Mood Stabilisers’ and Other Treatments for Bipolar Disorder
Allan H. Young and Sarah C. Wooderson

Anxiolytic and Hypnotic Drugs
David S. Baldwin and Nupur Tiwari

Drugs of Abuse
Anne Lingford-Hughes and Mark Daglish

Drugs for Dementia and Cognitive Impairment
Mehran Javeed, Ian M. Anderson and Iracema Leroi

Drugs Used for Personality Disorders and Behavioural Disturbance
Birgit A. Völlm and Ian M. Anderson

Drug Treatments for Child and Adolescent Disorders
David R. Coghill

Prescribing in Clinical Practice
Peter M. Haddad and Angelika Wieck

Clinical Trial Methodology
Stephen M. Lawrie and R. Hamish McAllister-Williams

Über Autor(innen)

Edited by

Ian M. Anderson, BA, MA, MBBS, MD, MRCP(UK), FRCPsych, is a professor of psychiatry in the Neuroscience and Psychiatry Unit at the University of Manchester, UK. He also is an honorary consultant psychiatrist at the Manchester Mental Health and Social Care Trust, UK. Dr. Anderson founded the Specialist Service for Affective Disorders in Manchester and was its director until 2011. His research interests include the aetiology and treatment of mood disorders, the mechanism of action of antidepressants and evidence-based psychiatry. He chaired the guideline development group for the 2009 update of the NICE depression clinical guideline and is an author on several consensus treatment guidelines from the British Association for Psychopharmacology (BAP). He is a past general secretary of the BAP.

R. Hamish McAllister-Williams, BSc, MBChB, PhD, MD, FRCPsych, is a reader in clinical psychopharmacology at the Institute of Neuroscience in Newcastle University, UK. He is also an honorary consultant psychiatrist in the Regional Affective Disorders Service at the Northumberland Tyne and Wear NHS Foundation Trust, UK. Dr. McAllister-Williams is the lead consultant in the tertiary level Regional Affective Disorders Service based in Newcastle for patients with treatment-refractory mood disorders. His research focuses on the pathophysiology and treatment of both bipolar and unipolar affective disorders, and he is an author of the British Association for Psychopharmacology (BAP) consensus guidelines for treating depression. He is a past general secretary of the BAP and was appointed its director of education in 2012.